Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study

Anne B Rossebø, Terje R Pedersen, Christopher Allen, Kurt Boman, John Chambers, Kenneth Egstrup, Eva Gerdts, Christa Gohlke-Bärwolf, Ingar Holme, V Antero Y Kesäniemi, William Malbecq, Christoph Nienaber, Simon Ray, Terje Skjaerpe, Kristian Wachtell, Ronnie Willenheimer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

 
Udgivelsesdato: Apr-1
OriginalsprogEngelsk
TidsskriftAmerican Journal of Cardiology
Vol/bind99
Udgave nummer7
Sider (fra-til)970-973
Antal sider3
ISSN0002-9149
DOI
StatusUdgivet - 1. apr. 2007

Fingeraftryk

Simvastatin
Lipids
Atherosclerotic Plaques
Hypercholesterolemia
LDL Cholesterol
HDL Cholesterol
Multicenter Studies
Body Mass Index
Placebos

Citer dette

Rossebø, Anne B ; Pedersen, Terje R ; Allen, Christopher ; Boman, Kurt ; Chambers, John ; Egstrup, Kenneth ; Gerdts, Eva ; Gohlke-Bärwolf, Christa ; Holme, Ingar ; Kesäniemi, V Antero Y ; Malbecq, William ; Nienaber, Christoph ; Ray, Simon ; Skjaerpe, Terje ; Wachtell, Kristian ; Willenheimer, Ronnie. / Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. I: American Journal of Cardiology. 2007 ; Bind 99, Nr. 7. s. 970-973.
@article{9d535ae0d3d611dcb2ba000ea68e967b,
title = "Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study",
abstract = "Aortic valve stenosis and atherosclerotic disease have several risk factors in common, in particular, hypercholesterolemia. Histologically, the diseased valves appear to have areas of inflammation much like atherosclerotic plaques. The effect of lipid-lowering therapy on the progression of aortic stenosis (AS) is unclear, and there are no randomized treatment trials evaluating cardiovascular morbidity and mortality in such patients. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study is a randomized, double-blind, placebo-controlled, multicenter study of a minimum 4 years' duration investigating the effect of lipid lowering with ezetimibe/simvastatin 10/40 mg/day in patients with asymptomatic AS with peak transvalvular jet velocity 2.5 to 4.0 m/s. Primary efficacy variables include aortic valve surgery and ischemic vascular events, including cardiovascular mortality, and second, the effect on echocardiographically evaluated progression of AS. The SEAS Study randomly assigned 1,873 patients (age 68+/-10 years, 39{\%} women, mean transaortic maximum velocity 3.1+/-0.5 m/s) from 173 sites. Other baseline characteristics were mean blood pressure of 145+/-20/82+/-10 mm Hg (51{\%} hypertensive); 55{\%} were current or previous smokers; and most were overweight (mean body mass index 26.9 kg/m2). At baseline, mean total cholesterol was 5.7+/-1.0 mmol/L (222 mg/dl), low-density lipoprotein cholesterol was 3.6+/-0.9 mmol/L (139 mg/dl), high-density lipoprotein cholesterol was 1.5+/-0.4 mmol/L (58 mg/dl), and triglycerides were 1.4+/-0.7 mmol/L (126 mg/dl). The SEAS Study is the largest randomized trial to date in patients with AS and will allow determination of the prognostic value of aggressive lipid lowering in such patients.",
keywords = "Aged, Aged, 80 and over, Anticholesteremic Agents, Aortic Valve Stenosis, Azetidines, Blood Flow Velocity, Cholesterol, HDL, Cholesterol, LDL, Disease Progression, Double-Blind Method, Drug Therapy, Combination, Echocardiography, Europe, Female, Follow-Up Studies, Humans, Male, Middle Aged, Simvastatin, Stroke Volume, Treatment Outcome, Triglycerides, Ventricular Function, Left",
author = "Rosseb{\o}, {Anne B} and Pedersen, {Terje R} and Christopher Allen and Kurt Boman and John Chambers and Kenneth Egstrup and Eva Gerdts and Christa Gohlke-B{\"a}rwolf and Ingar Holme and Kes{\"a}niemi, {V Antero Y} and William Malbecq and Christoph Nienaber and Simon Ray and Terje Skjaerpe and Kristian Wachtell and Ronnie Willenheimer",
year = "2007",
month = "4",
day = "1",
doi = "10.1016/j.amjcard.2006.10.064",
language = "English",
volume = "99",
pages = "970--973",
journal = "The American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier",
number = "7",

}

Rossebø, AB, Pedersen, TR, Allen, C, Boman, K, Chambers, J, Egstrup, K, Gerdts, E, Gohlke-Bärwolf, C, Holme, I, Kesäniemi, VAY, Malbecq, W, Nienaber, C, Ray, S, Skjaerpe, T, Wachtell, K & Willenheimer, R 2007, 'Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study', American Journal of Cardiology, bind 99, nr. 7, s. 970-973. https://doi.org/10.1016/j.amjcard.2006.10.064

Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. / Rossebø, Anne B; Pedersen, Terje R; Allen, Christopher; Boman, Kurt; Chambers, John; Egstrup, Kenneth; Gerdts, Eva; Gohlke-Bärwolf, Christa; Holme, Ingar; Kesäniemi, V Antero Y; Malbecq, William; Nienaber, Christoph; Ray, Simon; Skjaerpe, Terje; Wachtell, Kristian; Willenheimer, Ronnie.

I: American Journal of Cardiology, Bind 99, Nr. 7, 01.04.2007, s. 970-973.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study

AU - Rossebø, Anne B

AU - Pedersen, Terje R

AU - Allen, Christopher

AU - Boman, Kurt

AU - Chambers, John

AU - Egstrup, Kenneth

AU - Gerdts, Eva

AU - Gohlke-Bärwolf, Christa

AU - Holme, Ingar

AU - Kesäniemi, V Antero Y

AU - Malbecq, William

AU - Nienaber, Christoph

AU - Ray, Simon

AU - Skjaerpe, Terje

AU - Wachtell, Kristian

AU - Willenheimer, Ronnie

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Aortic valve stenosis and atherosclerotic disease have several risk factors in common, in particular, hypercholesterolemia. Histologically, the diseased valves appear to have areas of inflammation much like atherosclerotic plaques. The effect of lipid-lowering therapy on the progression of aortic stenosis (AS) is unclear, and there are no randomized treatment trials evaluating cardiovascular morbidity and mortality in such patients. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study is a randomized, double-blind, placebo-controlled, multicenter study of a minimum 4 years' duration investigating the effect of lipid lowering with ezetimibe/simvastatin 10/40 mg/day in patients with asymptomatic AS with peak transvalvular jet velocity 2.5 to 4.0 m/s. Primary efficacy variables include aortic valve surgery and ischemic vascular events, including cardiovascular mortality, and second, the effect on echocardiographically evaluated progression of AS. The SEAS Study randomly assigned 1,873 patients (age 68+/-10 years, 39% women, mean transaortic maximum velocity 3.1+/-0.5 m/s) from 173 sites. Other baseline characteristics were mean blood pressure of 145+/-20/82+/-10 mm Hg (51% hypertensive); 55% were current or previous smokers; and most were overweight (mean body mass index 26.9 kg/m2). At baseline, mean total cholesterol was 5.7+/-1.0 mmol/L (222 mg/dl), low-density lipoprotein cholesterol was 3.6+/-0.9 mmol/L (139 mg/dl), high-density lipoprotein cholesterol was 1.5+/-0.4 mmol/L (58 mg/dl), and triglycerides were 1.4+/-0.7 mmol/L (126 mg/dl). The SEAS Study is the largest randomized trial to date in patients with AS and will allow determination of the prognostic value of aggressive lipid lowering in such patients.

AB - Aortic valve stenosis and atherosclerotic disease have several risk factors in common, in particular, hypercholesterolemia. Histologically, the diseased valves appear to have areas of inflammation much like atherosclerotic plaques. The effect of lipid-lowering therapy on the progression of aortic stenosis (AS) is unclear, and there are no randomized treatment trials evaluating cardiovascular morbidity and mortality in such patients. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study is a randomized, double-blind, placebo-controlled, multicenter study of a minimum 4 years' duration investigating the effect of lipid lowering with ezetimibe/simvastatin 10/40 mg/day in patients with asymptomatic AS with peak transvalvular jet velocity 2.5 to 4.0 m/s. Primary efficacy variables include aortic valve surgery and ischemic vascular events, including cardiovascular mortality, and second, the effect on echocardiographically evaluated progression of AS. The SEAS Study randomly assigned 1,873 patients (age 68+/-10 years, 39% women, mean transaortic maximum velocity 3.1+/-0.5 m/s) from 173 sites. Other baseline characteristics were mean blood pressure of 145+/-20/82+/-10 mm Hg (51% hypertensive); 55% were current or previous smokers; and most were overweight (mean body mass index 26.9 kg/m2). At baseline, mean total cholesterol was 5.7+/-1.0 mmol/L (222 mg/dl), low-density lipoprotein cholesterol was 3.6+/-0.9 mmol/L (139 mg/dl), high-density lipoprotein cholesterol was 1.5+/-0.4 mmol/L (58 mg/dl), and triglycerides were 1.4+/-0.7 mmol/L (126 mg/dl). The SEAS Study is the largest randomized trial to date in patients with AS and will allow determination of the prognostic value of aggressive lipid lowering in such patients.

KW - Aged

KW - Aged, 80 and over

KW - Anticholesteremic Agents

KW - Aortic Valve Stenosis

KW - Azetidines

KW - Blood Flow Velocity

KW - Cholesterol, HDL

KW - Cholesterol, LDL

KW - Disease Progression

KW - Double-Blind Method

KW - Drug Therapy, Combination

KW - Echocardiography

KW - Europe

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Simvastatin

KW - Stroke Volume

KW - Treatment Outcome

KW - Triglycerides

KW - Ventricular Function, Left

U2 - 10.1016/j.amjcard.2006.10.064

DO - 10.1016/j.amjcard.2006.10.064

M3 - Journal article

C2 - 17398194

VL - 99

SP - 970

EP - 973

JO - The American Journal of Cardiology

JF - The American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -